| | | | |
CUSIP No. N0731H103 | | Schedule 13G | | Page 6 of 10 |
ITEM 1. | (a) Name of Issuer: |
ATAI Life Sciences N.V. (the “Issuer”).
| (b) | Address of Issuer’s Principal Executive Offices: |
ATAI Life Sciences N.V., Wallstraße 16, 10179, Berlin, Germany.
ITEM 2. | (a) Name of Person Filing: |
Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:
Apeiron Investment Group Ltd. (“Apeiron”);
Apeiron Presight Capital Fund II, L.P. (“Presight II”);
Presight Capital Management I, L.L.C. (“Presight Management”);
Fabian Hansen; and
Christian Angermayer.
| (b) | Address or Principal Business Office: |
The principal business address of each of the Reporting Persons is 66 & 67 Amery Street, SLM1707, Sliema, Malta.
| (c) | Citizenship of each Reporting Person is: |
Presight II and Presight Management are organized under the laws of the State of Delaware. Apeiron is organized under the laws of Malta. Each of Messrs. Hansen and Angermayer is a German citizen.
| (d) | Title of Class of Securities: |
Common shares, par value €0.1 per share (“Common Shares”).
N0731H103
Not applicable.
(a-c)